Navigation Links
Omeros and BlueCrest Announce $20 Million Debt Facility
Date:9/24/2008

SEATTLE and CHICAGO, Sept. 24 /PRNewswire/ -- Omeros Corporation, a Seattle-based biopharmaceutical company, today announced the establishment of a $20 million debt facility with BlueCrest Capital Finance. The facility consists of a $5 million term loan drawn by Omeros at closing and the right, subject to certain conditions, to access up to the remaining $15 million. Other terms were not disclosed.

"This credit facility provides us with increased financial flexibility as we continue to expand our clinical programs and advance our deep preclinical pipeline," said Gregory A. Demopulos, M.D., Chairman and CEO of Omeros. "The BlueCrest team has a strong track record, and agreed to terms that meet our business objectives."

"Our decision to make a significant investment in Omeros was driven by the quality of its management team, program portfolio, intellectual property and business strategy," said Chris York, Managing Director of BlueCrest Capital Finance. "We are excited to be working with Omeros and look forward to the Company's future achievements."

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and central nervous system disorders. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. For more information on Omeros, visit the Company's Web site at http://www.omeros.com.

About BlueCrest Capital Finance

BlueCrest Capital Finance, L.P., a US based commercial finance company, provides debt financing solutions to development stage companies in a broad range of industry sectors including IT, Communications, Hardware, Software, Semi-Conductor, Electronics, Energy, Medical Device and Life Science. The team, which has been together continuously since 1998, pursues debt transactions in the $1-25 million range and has consummated approximately 800 transactions with total commitments in excess of $1.8 billion.


'/>"/>
SOURCE Omeros Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
2. Omeros Appoints David A. Mann to its Board of Directors
3. Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
4. Chromos announces timing of closing of Arrangement
5. TIBCO Spotfire and INTEGROMICS Announce Genomics Data Analysis Solution to Radically Speed Drug Research and Development
6. Environmental Tectonics Corporation Announces a Multiple Sale for Monoplace Hyperbaric Chambers
7. AHIC Successor, Inc. Announces Board of Directors
8. InspireMD Announces Enrollment of First Patients in the MGuard(TM) Acute Myocardial Infarction Clinical Trial Data Will be Used to Confirm Initial Positive Results
9. Affitech Announces Second Milestone in Roche Antibody Discovery Collaboration
10. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
11. Emisphere Announces Recruitment Phase III Study for Oral Osteoarthritis Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/14/2017)... ... 14, 2017 , ... The Conference Forum has confirmed the one-day ... on September 6, 2017 at the Marriott Copley Place in Boston, MA. , Returning ... and Regulatory Strategy, Pfizer Innovative Research Lab, Pfizer, who leads 19 industry speakers in ...
(Date:8/11/2017)... , ... August 11, 2017 , ... ... production, and, in particular, more natural alternatives to synthetic ingredients,” said Matt Hundt, ... Third Wave, with the established manufacturing presence and know-how of Biorigin will allow ...
(Date:8/10/2017)... ... 09, 2017 , ... Each year in the United States more than 300,000 ... an independent lifestyle and, even worse, the one-year mortality rate is high, ranging from ... University of California Davis Medical Center (Sacramento) and Second Xiangya Hospital of the Central-South ...
(Date:8/10/2017)... and CARDIFF, UK (PRWEB) , ... August 10, ... ... photonics, has announced an agreement establishing Kinokuniya Company Ltd. as its exclusive sales ... as the exclusive sales representative for the SPIE Digital Library in Japan. , ...
Breaking Biology Technology:
(Date:4/11/2017)... GARDENS, Fla. , April 11, 2017 /PRNewswire/ ... management and secure authentication solutions, today announced that ... by Intelligence Advanced Research Projects Activity (IARPA) to ... IARPA,s Thor program. "Innovation has been ... and IARPA,s Thor program will allow us to ...
(Date:4/5/2017)... 2017  The Allen Institute for Cell Science today ... one-of-a-kind portal and dynamic digital window into the human ... first application of deep learning to create predictive models ... and a growing suite of powerful tools. The Allen ... future publicly available resources created and shared by the ...
(Date:3/30/2017)... , March 30, 2017  On April 6-7, 2017, ... the Genome hackathon at Microsoft,s headquarters in ... competition will focus on developing health and wellness apps ... Hack the Genome is the first hackathon ... The world,s largest companies in the genomics, tech and ...
Breaking Biology News(10 mins):